KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Finished Goods (2018 - 2026)

Twist Bioscience has reported Finished Goods over the past 9 years, most recently at $5.0 million for Q1 2026.

  • Quarterly Finished Goods changed 0.06% to $5.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Mar 2026, changed 0.06% year-over-year, with the annual reading at $5.9 million for FY2025, 26.8% up from the prior year.
  • Finished Goods was $5.0 million for Q1 2026 at Twist Bioscience, down from $5.9 million in the prior quarter.
  • Over five years, Finished Goods peaked at $9.6 million in Q1 2022 and troughed at $3.9 million in Q3 2023.
  • The 5-year median for Finished Goods is $5.3 million (2023), against an average of $5.9 million.
  • Year-over-year, Finished Goods skyrocketed 415.24% in 2022 and then crashed 48.71% in 2023.
  • A 5-year view of Finished Goods shows it stood at $7.4 million in 2022, then plummeted by 36.47% to $4.7 million in 2023, then grew by 2.75% to $4.8 million in 2024, then rose by 22.43% to $5.9 million in 2025, then decreased by 15.41% to $5.0 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Finished Goods are $5.0 million (Q1 2026), $5.9 million (Q4 2025), and $5.9 million (Q3 2025).